| A Study of Inhaled AZD8630 in Adolescents With Asthma (NCT07065331) | AstraZeneca | 2025-06-11 |
| ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (NCT06973161) | AstraZeneca | 2025-06-10 |
| A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH (NCT07000136) | AstraZeneca | 2025-06-10 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort (NCT07024823) | AstraZeneca | 2025-06-09 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants. (NCT06995820) | AstraZeneca | 2025-06-06 |
| Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia (NCT07088991) | AstraZeneca | 2025-06-06 |
| A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (NCT07013643) | AstraZeneca | 2025-06-04 |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event (NCT07000357) | AstraZeneca | 2025-06-04 |
| Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap (NCT07103629) | AstraZeneca | 2025-05-31 |
| A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event (NCT07000123) | AstraZeneca | 2025-05-28 |
| A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (NCT06942936) | AstraZeneca | 2025-05-28 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (NCT06980428) | AstraZeneca | 2025-05-27 |
| The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. (NCT07069725) | AstraZeneca | 2025-05-26 |
| A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z (NCT06929260) | AstraZeneca | 2025-05-21 |
| This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (NCT07017179) | AstraZeneca | 2025-05-20 |
| A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462 (NCT06989983) | AstraZeneca | 2025-05-20 |
| NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife) (NCT06890273) | AstraZeneca | 2025-05-20 |
| Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (NCT06960577) | AstraZeneca | 2025-05-15 |
| Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components. (NCT06899633) | AstraZeneca | 2025-05-15 |
| Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (NCT06909253) | AstraZeneca | 2025-05-15 |
| A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine (NCT06974565) | AstraZeneca | 2025-05-12 |
| A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants (NCT06973005) | AstraZeneca | 2025-05-08 |
| A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria (NCT06942910) | AstraZeneca | 2025-05-07 |
| A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (NCT06948747) | AstraZeneca | 2025-05-06 |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (NCT06921785) | AstraZeneca | 2025-05-06 |
| Study for AZD4360 in Participants With Advanced Solid Tumours (NCT06921928) | AstraZeneca | 2025-04-29 |
| AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database (NCT06548152) | AstraZeneca | 2025-04-28 |
| A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants (NCT06948006) | AstraZeneca | 2025-04-23 |
| A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity (NCT06942923) | AstraZeneca | 2025-04-22 |
| A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants (NCT06925854) | AstraZeneca | 2025-04-17 |
| Imjudo & Imfinzi PMS (NCT06544629) | AstraZeneca | 2025-04-14 |
| A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils (NCT06897748) | AstraZeneca | 2025-04-12 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer (NCT06868277) | AstraZeneca | 2025-04-10 |
| An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab (NCT06908577) | AstraZeneca | 2025-04-07 |
| AZD5305 hADME in Patients With Advanced Solid Malignancies (NCT06713369) | AstraZeneca | 2025-04-02 |
| A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (NCT06943833) | AstraZeneca | 2025-03-31 |
| Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC (NCT07024680) | AstraZeneca | 2025-03-31 |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (NCT06750289) | AstraZeneca | 2025-03-28 |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (NCT06989112) | AstraZeneca | 2025-03-27 |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (NCT06795022) | AstraZeneca | 2025-03-27 |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (NCT06932263) | AstraZeneca | 2025-03-26 |
| Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (NCT06899061) | AstraZeneca | 2025-03-25 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) (NCT06878261) | AstraZeneca | 2025-03-25 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) (NCT06883305) | AstraZeneca | 2025-03-18 |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (NCT06677060) | AstraZeneca | 2025-03-14 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (NCT06792695) | AstraZeneca | 2025-03-12 |
| Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (NCT06851858) | AstraZeneca | 2025-03-12 |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT06879041) | AstraZeneca | 2025-03-10 |
| A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004 (NCT06857695) | AstraZeneca | 2025-03-06 |
| An Ophthalmic Safety Study in Patients With Breast Cancer (NCT06767462) | AstraZeneca | 2025-03-05 |
| Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease (NCT06824987) | AstraZeneca | 2025-03-05 |
| A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (NCT06742723) | AstraZeneca | 2025-03-03 |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (NCT06764875) | AstraZeneca | 2025-03-01 |
| Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus (NCT06673043) | AstraZeneca | 2025-02-28 |
| Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma. (NCT06732882) | AstraZeneca | 2025-02-27 |
| A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants (NCT06846528) | AstraZeneca | 2025-02-26 |
| Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 (NCT06845813) | AstraZeneca | 2025-02-24 |
| A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (NCT06862791) | AstraZeneca | 2025-02-18 |
| A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (NCT06644924) | AstraZeneca | 2025-02-10 |
| Real-life Treatment Outcomes of Ravulizumab in PNH (NCT06633536) | AstraZeneca | 2025-02-06 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure (NCT06651970) | AstraZeneca | 2025-02-04 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 (NCT06812780) | AstraZeneca | 2025-02-04 |
| Study That Will Evaluate the Brazilian Population With COPD. (NCT06780046) | AstraZeneca | 2025-01-31 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (NCT06564038) | AstraZeneca | 2025-01-30 |
| Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer (NCT06727227) | AstraZeneca | 2025-01-29 |
| A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults (NCT06723756) | AstraZeneca | 2025-01-23 |
| Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD) (NCT06744335) | AstraZeneca | 2025-01-20 |
| Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib (NCT06754761) | AstraZeneca | 2025-01-17 |
| A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING) (NCT06575517) | AstraZeneca | 2025-01-13 |
| A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (NCT06764186) | AstraZeneca | 2025-01-07 |
| Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients (NCT06429761) | AstraZeneca | 2025-01-02 |
| A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) (NCT06749457) | AstraZeneca | 2024-12-30 |
| REBECCA Real-world Early BrEast CanCer mAnagement (NCT06856343) | AstraZeneca | 2024-12-30 |
| A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain (NCT06746116) | AstraZeneca | 2024-12-30 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. (NCT06742853) | AstraZeneca | 2024-12-20 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 (NCT06813781) | AstraZeneca | 2024-12-19 |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 (NCT06742762) | AstraZeneca | 2024-12-17 |
| UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance (NCT06726720) | AstraZeneca | 2024-12-16 |
| Study of Patient With Frequent COPD Exacerbations (NCT07221981) | AstraZeneca | 2024-12-16 |
| Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy (NCT06681324) | AstraZeneca | 2024-12-11 |
| A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. (NCT06675175) | AstraZeneca | 2024-12-09 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (NCT06834932) | AstraZeneca | 2024-12-06 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. (NCT06750276) | AstraZeneca | 2024-12-06 |
| A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants (NCT06715670) | AstraZeneca | 2024-12-05 |
| A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (NCT06706817) | AstraZeneca | 2024-12-03 |
| Observational Study on the Treatment of Patients With Metastatic Breast Cancer (NCT06676436) | AstraZeneca | 2024-11-30 |
| This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE (NCT06698900) | AstraZeneca | 2024-11-29 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC (NCT06627647) | AstraZeneca | 2024-11-27 |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (NCT06526793) | AstraZeneca | 2024-11-27 |
| Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study (NCT06494241) | AstraZeneca | 2024-11-22 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (NCT06692738) | AstraZeneca | 2024-11-18 |
| A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment (NCT06661733) | AstraZeneca | 2024-11-18 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants (NCT06693765) | AstraZeneca | 2024-11-18 |
| Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany (NCT06675552) | AstraZeneca | 2024-11-15 |
| An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients (NCT06605885) | AstraZeneca | 2024-11-14 |
| Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle (NCT06646419) | AstraZeneca | 2024-11-13 |
| VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain (NCT06635499) | AstraZeneca | 2024-11-13 |
| Covid-19 Data Analyses in Brazil (NCT06652451) | AstraZeneca | 2024-11-12 |
| A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus (NCT06703658) | AstraZeneca | 2024-11-02 |
| A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential (NCT06657105) | AstraZeneca | 2024-11-01 |